Synaptogenix, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87167T2015
USD
6.67
0.57 (9.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

98.82 k

Shareholding (Mar 2025)

FII

0.08%

Held by 4 FIIs

DII

98.87%

Held by 1 DIIs

Promoter

0.00%

How big is Synaptogenix, Inc.?

22-Jun-2025

As of Jun 18, Synaptogenix, Inc. has a market capitalization of 5.45 million, with net sales of 0.00 million and a net profit of -12.17 million over the latest four quarters. The company reported shareholder's funds of 5.86 million and total assets of 17.73 million as of Dec 24.

Market Cap: As of Jun 18, Synaptogenix, Inc. has a market capitalization of 5.45 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Synaptogenix, Inc. reported net sales of 0.00 million and a net profit of -12.17 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 5.86 million and total assets of 17.73 million.

Read More

What does Synaptogenix, Inc. do?

22-Jun-2025

Synaptogenix, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of $5.45 million and no recent profits. Key financial metrics include a negative P/E ratio, a dividend yield of 0.00%, and a return on equity of -113.14%.

Overview: <BR>Synaptogenix, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 5.45 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.87 <BR>Return on Equity: -113.14% <BR>Price to Book: 1.05<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Synaptogenix, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Synaptogenix, Inc. shows a mildly bullish trend with daily moving averages indicating mild bullishness, but caution is advised due to bearish signals from the monthly RSI and mixed indicators from the weekly MACD and KST, despite a strong year-to-date performance of 80.69% compared to the S&P 500's 12.22%.

As of 25 August 2025, the technical trend for Synaptogenix, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, along with weekly Bollinger Bands showing bullish signals. However, the weekly MACD and KST are mildly bearish, which tempers the overall bullish outlook. The monthly RSI is bearish, suggesting caution. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 year-to-date with a return of 80.69% compared to the S&P 500's 12.22%, but it has significantly underperformed over the past three years with a return of -96.84% against the S&P 500's 70.41%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 22 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-39.79%

stock-summary
Price to Book

1.22

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.17%
0%
11.17%
6 Months
156.54%
0%
156.54%
1 Year
120.86%
0%
120.86%
2 Years
0.72%
0%
0.72%
3 Years
9.52%
0%
9.52%
4 Years
-96.96%
0%
-96.96%
5 Years
0%
0%
0.0%

Synaptogenix, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
8.39%
EBIT to Interest (avg)
-11.62
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.87
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.47%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.65
EV to EBIT
1.86
EV to EBITDA
1.86
EV to Capital Employed
1.19
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
64.03%
ROE (Latest)
-113.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.06%)

Foreign Institutions

Held by 4 Foreign Institutions (0.08%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -1,246.15% vs 68.29% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-1.60",
          "chgp": "-68.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.50",
          "val2": "-1.30",
          "chgp": "-1,246.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-684,836.70%",
          "val2": "0.00%",
          "chgp": "-68,483.67%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -113.33% vs -7.14% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.80",
          "val2": "-8.30",
          "chgp": "18.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.60",
          "val2": "0.60",
          "chgp": "-1,200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.80",
          "val2": "-6.00",
          "chgp": "-113.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.70
-1.60
-68.75%
Interest
0.00
0.00
Exceptional Items
-15.00
-0.00
Consolidate Net Profit
-17.50
-1.30
-1,246.15%
Operating Profit Margin (Excl OI)
-684,836.70%
0.00%
-68,483.67%
USD in Million.
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -1,246.15% vs 68.29% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.80
-8.30
18.07%
Interest
0.00
0.00
Exceptional Items
-6.60
0.60
-1,200.00%
Consolidate Net Profit
-12.80
-6.00
-113.33%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -113.33% vs -7.14% in Dec 2023

stock-summaryCompany CV
About Synaptogenix, Inc. stock-summary
stock-summary
Synaptogenix, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available